{
    "clinical_study": {
        "@rank": "107541", 
        "acronym": "VD2000", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D3", 
                "arm_group_type": "Experimental", 
                "description": "25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "administered elemental calcium 200mg daily for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "In many observational studies, vitamin D deficiency is related to glucose intolerance and\n      diabetes. But there little randomized, controlled interventional studies that evaluate the\n      effect of vitamin D in type 2 diabetes.\n\n      Investigators investigate the effect of high dose (2000IU) 25-hydroxy vitamin D on type 2\n      diabetes in glycemic controls, non-alcholic fatty liver disease, and arterial stiffness, and\n      bone turnover markers."
        }, 
        "brief_title": "The Effect of Vitamin D Supplementation in Type 2 Diabetes", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "DIABETES MELLITUS", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "After informed consent, investigators randomized 180 type 2 diabetes into interventiona\n      group (25-hydroxy vitamin d 2000 IU+ elemental calcium 200mg per day) or placebo group\n      (elemental calcium 200mg per day). The participants should control diabetes by oral\n      medications or lifestyle intervention at the intervention period. Investigators exclude the\n      participants who took vitamin D or calcium or anti-osteoporotic drugs. Investigators also\n      exclude renal insufficiency (Cr>1.5 in men or Cr>1.4 in women) or heavy alcoholics.\n\n      Investigators followed the participants for 24 weeks. After randomization, investigators\n      checked HbA1c,glucose, calcium, 25-hydroxyvitamin d, AST, ALT,Creatinine, Parathyroid\n      hormone, bone-specific alkaline phosphatase, serum CTX,  brachial-ankle pulse wave velocity,\n      central blood pressure, and aortic augmentation index, and precontrast liver computed\n      tomography. Also investigators checked body weight, height, and peripheral blood pressure.\n\n      At 12 weeks, investigators checked HbA1c, 25-hydroxy vitamin D, AST, ALT, calcium, and\n      creatinine.\n\n      At the end of the study(at 24 weeks), investigators checked HbA1c, glucose, AST, ALT,\n      Creatinine, calcium, bone-specific alkaline phosphatase, serum CTX, brachial-ankle pulse\n      wave velocity, central blood pressure, aortic augmentation index, and precontrast liver\n      computed tomography.\n\n      After the study completed, investiators compared the data of interventional groups and\n      placebo groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  TYPE 2 DIABETES MELLITUS PATIENTS WHO CONTROL GLUCOSE BY ORAL ANTIBIABETIC DRUGS OR\n             LIFESTYLE ONLY\n\n          -  DID NOT CHANGE ANTIDIABETIC DRUG BEFORE THE STUDY FOR 2 MONTHS\n\n          -  normal physical activity\n\n          -  30 to 69 years\n\n          -  >=6.5% OR <8.0% OF HbA1c\n\n        Exclusion Criteria:\n\n          -  Creatinine>1.5 in men, >1.4 in women\n\n          -  heavy alcoholics\n\n          -  who took calcium or vitamin d or anti-osteoporosis drug within 3 months before  the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "158", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854463", 
            "org_study_id": "CSHH2011-64", 
            "secondary_id": "KDA2010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D3", 
                "description": "2000IU per day", 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Drug", 
                "other_name": "dicamax d"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "elemental calcium 200mg per day per 24 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "calcium"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DIABETES MELLITUS", 
            "VITAMIN D", 
            "ARTERIAL STIFFNESS", 
            "FATTY LIVER", 
            "BONE TURNOVER"
        ], 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chuncheon", 
                    "country": "Korea, Republic of", 
                    "state": "Gangwon-do", 
                    "zip": "200704"
                }, 
                "name": "Chuncheon Sacred Heart Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes", 
        "other_outcome": {
            "description": "precontrast liver computed tomography AST, ALT calcium, PTH, bone specific alkaline phosphatase, serum CTX, calcium", 
            "measure": "non-alcoholic fatty liver diseases and bone turnover marker", 
            "safety_issue": "Yes", 
            "time_frame": "at 0 and 24- week"
        }, 
        "overall_official": {
            "affiliation": "Hallym University Medical Center", 
            "last_name": "OHKHYUN RYU, PROFESSOR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Investigators checked glycemic control status at the enrollment, 12-week, 24- week by HbA1c", 
            "measure": "glycemic control", 
            "safety_issue": "Yes", 
            "time_frame": "0, 12week, and  24week"
        }, 
        "reference": {
            "PMID": "23561637", 
            "citation": "Breslavsky A, Frand J, Matas Z, Boaz M, Barnea Z, Shargorodsky M. Effect of high doses of vitamin D on arterial properties, adiponectin, leptin and glucose homeostasis in type 2 diabetic patients. Clin Nutr. 2013 Feb 27. doi:pii: S0261-5614(13)00047-2. 10.1016/j.clnu.2013.01.020. [Epub ahead of print]"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854463"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chuncheon Sacred Heart Hospital", 
            "investigator_full_name": "OHKHYUN RYU", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "central blood pressure brachial-ankle pulse wave velocity aortic augmentation index", 
            "measure": "arterial stiffenss", 
            "safety_issue": "Yes", 
            "time_frame": "at 0 and  24-week"
        }, 
        "source": "Chuncheon Sacred Heart Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Korean Diabetes Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chuncheon Sacred Heart Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}